Last reviewed · How we verify
Ropivacaine 0,75% in PENG block
Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia.
Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce regional anesthesia. Used for Regional anesthesia via PENG block for lower limb surgery and postoperative analgesia.
At a glance
| Generic name | Ropivacaine 0,75% in PENG block |
|---|---|
| Sponsor | University of Liege |
| Drug class | Local anesthetic (amide) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia/Pain Management |
| Phase | FDA-approved |
Mechanism of action
Ropivacaine is an amide-type local anesthetic that reversibly inhibits sodium influx through voltage-gated sodium channels in nerve cell membranes. By blocking sodium channel conductance, it prevents depolarization and action potential generation in sensory and motor nerves. The PENG (Pectineus Fascia Iliopsoas Nerve Groove) block is a regional anesthesia technique that delivers ropivacaine to anesthetize the femoral nerve and its branches for lower limb anesthesia and analgesia.
Approved indications
- Regional anesthesia via PENG block for lower limb surgery and postoperative analgesia
Common side effects
- Transient neurological symptoms
- Systemic toxicity (CNS and cardiac)
- Local tissue irritation
- Hypotension
- Bradycardia
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0,75% in PENG block CI brief — competitive landscape report
- Ropivacaine 0,75% in PENG block updates RSS · CI watch RSS
- University of Liege portfolio CI